Anna Przeklasa-Muszyńska1, Magdalena Kocot-Kępska2, Jan Dobrogowski2, Maciej Wiatr3, Joanna Mika4. 1. Department of Pain Research and Treatment, Chair of Anesthesiology and Intensive Therapy, Jagiellonian University Medica l College, Kraków, Poland. Electronic address: aprzemusz@wp.pl. 2. Department of Pain Research and Treatment, Chair of Anesthesiology and Intensive Therapy, Jagiellonian University Medica l College, Kraków, Poland. 3. Department of Otolaryngology, Jagiellonian University Medical College, Kraków, Poland. 4. Institute of Pharmacology, Polish Academy of Sciences, Department of Pain Pharmacology, Kraków, Poland. Electronic address: joasia272@onet.eu.
Abstract
BACKGROUND: Headache is one of the most common conditions troubling nearly 45% of the world's population. Migraine headache itself, being more common among women, affects 7-18% of people. As much as 20-30% of the population report accompanying aura and neurological symptoms. In many cases, migraine headache can be effectively treated with suitably selected pharmacotherapies which include drugs used in symptomatic treatment. Frequent occurrence of the condition is treated with prophylaxis, which often fails. Neuromodulating methods are part of the multidirectional treatment and they may be valuable complement to pharmacotherapy. METHODS: Our study evaluates the impact of the transcranial direct current stimulation (tDCS) on the consumption of drugs and on pain conditions (frequency, duration, intensity). We recruited 50 patients with migraine headache (30 with aura, 20 without aura) refractory to pharmacological therapy. In 30 patients (18 with aura, 12 without aura) previous unsatisfactory treatment was supplemented with tDCS performed tenfold. 20 patients (12 with aura, 8 without aura) from a control group were treated with pharmacological methods The observation continued for 30 days after the stimulation. RESULTS: After tDCS, a reduction in the consumption of analgesics and triptans was reported. Additionally, we monitored pain intensity decrease during pain episodes, duration of episodes and the number of pain days. The subjective assessment of pain reduction in migraine patients encompassed 36-40% after tDCS much more effective in comparison to group with only pharmacotherapy (10-12.5%). CONCLUSIONS: The study suggests that tDCS may be safe and useful clinical tool in migraine prophylaxis and treatment.
BACKGROUND:Headache is one of the most common conditions troubling nearly 45% of the world's population. Migraineheadache itself, being more common among women, affects 7-18% of people. As much as 20-30% of the population report accompanying aura and neurological symptoms. In many cases, migraineheadache can be effectively treated with suitably selected pharmacotherapies which include drugs used in symptomatic treatment. Frequent occurrence of the condition is treated with prophylaxis, which often fails. Neuromodulating methods are part of the multidirectional treatment and they may be valuable complement to pharmacotherapy. METHODS: Our study evaluates the impact of the transcranial direct current stimulation (tDCS) on the consumption of drugs and on pain conditions (frequency, duration, intensity). We recruited 50 patients with migraineheadache (30 with aura, 20 without aura) refractory to pharmacological therapy. In 30 patients (18 with aura, 12 without aura) previous unsatisfactory treatment was supplemented with tDCS performed tenfold. 20 patients (12 with aura, 8 without aura) from a control group were treated with pharmacological methods The observation continued for 30 days after the stimulation. RESULTS: After tDCS, a reduction in the consumption of analgesics and triptans was reported. Additionally, we monitored pain intensity decrease during pain episodes, duration of episodes and the number of pain days. The subjective assessment of pain reduction in migrainepatients encompassed 36-40% after tDCS much more effective in comparison to group with only pharmacotherapy (10-12.5%). CONCLUSIONS: The study suggests that tDCS may be safe and useful clinical tool in migraine prophylaxis and treatment.
Authors: Anthony G Mansour; Rechdi Ahdab; Georges Khazen; Christelle El-Khoury; Toni M Sabbouh; Maher Salem; Wissam Yamak; Moussa A Chalah; Samar S Ayache; Naji Riachi Journal: J Clin Med Date: 2020-04-10 Impact factor: 4.241